See more : Science Strategic Acquisition Corp. Alpha (SSAAU) Income Statement Analysis – Financial Results
Complete financial analysis of Oncolytics Biotech Inc. (ONCY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oncolytics Biotech Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Simply Better Brands Corp. (PKANF) Income Statement Analysis – Financial Results
- Digital Realty Trust, Inc. (DLR) Income Statement Analysis – Financial Results
- Advanced Human Imaging Limited (AHI.AX) Income Statement Analysis – Financial Results
- New Concept Energy, Inc. (GBR) Income Statement Analysis – Financial Results
- CVS Health Corporation (CVS) Income Statement Analysis – Financial Results
Oncolytics Biotech Inc. (ONCY)
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 783.46K | 699.76K | 313.31K | 208.87K | 0.00 | 310.00K | 1.00 |
| Cost of Revenue | 403.00K | 392.00K | 452.07K | 446.19K | 485.57K | 95.38K | 90.77K | 162.23K | 180.41K | 0.00 | 0.00 | 4.85M | 5.33M | 4.19M | 3.78M | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -403.00K | -392.00K | -452.07K | -446.19K | -485.57K | -95.38K | -90.77K | -162.23K | -180.41K | 0.00 | 0.00 | 0.00 | -5.33M | -4.19M | -3.78M | -4.31M | 0.00 | 0.00 | 783.46K | 699.76K | 313.31K | 208.87K | 0.00 | 310.00K | 1.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 17.71M | 15.43M | 12.92M | 12.94M | 11.13M | 9.42M | 9.39M | 9.77M | 8.60M | 13.82M | 18.51M | 31.40M | 23.39M | 12.19M | 12.15M | 13.35M | 11.32M | 10.54M | 9.31M | 7.11M | 3.31M | 4.28M | 5.12M | 3.69M | 486.66K |
| General & Administrative | 16.08M | 11.49M | 13.32M | 12.51M | 0.00 | 0.00 | 0.00 | 5.36M | 5.14M | 0.00 | 372.74K | 730.75K | 1.14M | 3.25M | 4.40M | 64.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -452.49K | -445.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.08M | 11.49M | 12.86M | 12.07M | 8.84M | 7.08M | 6.21M | 5.36M | 5.14M | 5.00M | 372.74K | 730.75K | 1.14M | 3.25M | 4.40M | 64.04K | 4.53M | 4.03M | 3.15M | 5.47M | 2.95M | 2.10M | 1.56M | 1.06M | 89.03K |
| Other Expenses | 0.00 | 0.00 | 13.31M | 12.51M | 9.56M | 7.24M | 6.21M | 162.23K | 180.41K | 5.00M | 5.02M | 4.55M | 0.00 | 409.84K | 425.40K | 341.97K | 5.53M | 4.96M | 4.00M | 6.22M | 3.62M | 2.68M | 2.02M | 1.27M | 90.71K |
| Operating Expenses | 33.79M | 26.92M | 26.23M | 25.46M | 20.69M | 16.66M | 15.61M | 15.29M | 13.92M | 18.82M | 23.90M | 36.69M | 28.72M | 15.51M | 17.00M | 13.76M | 16.85M | 15.50M | 13.31M | 13.33M | 6.93M | 6.96M | 7.14M | 4.96M | 577.37K |
| Cost & Expenses | 33.79M | 26.92M | 26.23M | 25.46M | 20.69M | 16.66M | 15.61M | 15.29M | 13.92M | 18.82M | 23.90M | 36.69M | 28.72M | 19.70M | 17.00M | 18.07M | 16.85M | 15.50M | 13.31M | 13.33M | 6.93M | 6.96M | 7.14M | 4.96M | 577.37K |
| Interest Income | 1.33M | 528.00K | 98.61K | 121.19K | 179.28K | 173.50K | 130.10K | 163.90K | 197.86K | 210.39K | 371.49K | 345.00K | 416.25K | 76.93K | 30.83K | 519.26K | 1.21M | 1.23M | 783.46K | 699.76K | 313.31K | 208.87K | 655.21K | 905.69K | 0.00 |
| Interest Expense | 0.00 | 528.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 81.00K | 392.00K | 452.07K | 446.19K | 485.57K | 95.38K | 90.77K | 162.23K | 180.41K | 163.50K | 131.62K | 109.28K | 92.59K | 63.16K | 257.25K | 410.25K | 1.00M | 926.68K | 855.99K | 751.76K | 663.52K | 574.24K | 465.45K | 205.20K | 1.68K |
| EBITDA | -33.71M | -26.83M | -25.66M | -25.37M | -20.02M | -17.18M | -15.51M | -15.13M | -13.74M | -18.66M | -23.77M | -36.58M | -27.93M | -19.29M | -16.75M | -17.66M | -15.83M | -14.53M | -12.46M | -12.58M | -5.95M | -6.18M | -6.67M | -4.44M | -575.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -753.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,457.86% | -1,651.52% | -1,296.66% | -2,957.46% | 0.00% | -1,432.41% | -57,569,100.00% |
| Operating Income | -33.79M | -28.57M | -26.23M | -25.46M | -20.69M | -16.66M | -15.61M | -15.29M | -13.92M | -18.82M | -23.90M | -36.69M | -28.72M | -20.04M | -17.00M | -18.07M | -16.85M | -15.50M | -12.53M | -12.63M | -6.62M | -6.75M | -7.14M | -4.65M | -577.37K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -756.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,599.39% | -1,805.23% | -2,112.40% | -3,232.38% | 0.00% | -1,498.60% | -57,737,000.00% |
| Total Other Income/Expenses | 6.14M | 2.17M | -20.06K | 2.95M | -12.43M | 173.50K | 130.10K | 163.90K | 197.86K | 210.39K | 371.49K | 345.00K | -283.43K | 76.93K | 30.83K | 519.26K | 1.20M | 1.20M | 529.09K | -323.88K | -1.89M | 0.00 | 655.21K | 905.69K | 0.00 |
| Income Before Tax | -27.66M | -24.75M | -26.25M | -22.51M | -33.12M | -16.49M | -15.48M | -15.13M | -13.72M | -18.61M | -23.53M | -36.34M | -29.00M | -19.97M | -16.97M | -17.55M | -15.64M | -14.30M | -12.78M | -12.96M | -8.51M | -6.75M | -6.48M | -3.74M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -749.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,631.66% | -1,851.52% | -2,716.36% | -3,232.38% | 0.00% | -1,206.44% | 0.00% |
| Income Tax Expense | 97.00K | 84.00K | 49.43K | -2.95M | 12.43M | 548.04K | 141.50K | 9.37K | 3.15K | 6.78K | 5.41K | 30.47K | 40.00K | 7.61K | 23.04K | 0.00 | -1.20M | -1.20M | -1.53K | 323.88K | 33.55K | -659.90K | -310.57K | -126.81K | -2.91K |
| Net Income | -27.75M | -24.84M | -26.30M | -19.55M | -45.55M | -17.04M | -15.62M | -15.14M | -13.72M | -18.62M | -23.53M | -36.37M | -29.04M | -19.97M | -17.00M | -17.55M | -15.64M | -14.30M | -12.78M | -12.96M | -8.54M | -6.09M | -6.17M | -3.61M | -574.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -749.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,631.47% | -1,851.52% | -2,727.07% | -2,916.44% | 0.00% | -1,165.53% | -57,446,200.00% |
| EPS | -0.41 | -0.43 | -0.49 | -0.48 | -2.06 | -1.06 | -1.12 | -1.20 | -1.16 | -2.01 | -2.68 | -4.54 | -3.89 | -3.04 | -3.27 | -4.03 | -3.68 | -3.74 | -3.71 | -4.31 | -3.48 | -2.74 | -3.17 | -2.09 | -0.93 |
| EPS Diluted | -0.41 | -0.43 | -0.49 | -0.48 | -2.06 | -1.06 | -1.12 | -1.20 | -1.16 | -2.01 | -2.68 | -4.54 | -3.89 | -3.04 | -3.27 | -4.03 | -3.68 | -3.74 | -3.71 | -4.31 | -3.48 | -2.74 | -3.17 | -1.98 | -0.93 |
| Weighted Avg Shares Out | 67.62M | 58.03M | 53.51M | 40.34M | 22.14M | 16.02M | 13.94M | 12.62M | 11.85M | 9.25M | 8.79M | 8.01M | 7.46M | 6.58M | 5.20M | 4.35M | 4.26M | 3.82M | 3.44M | 3.01M | 2.45M | 2.23M | 1.95M | 1.73M | 616.48K |
| Weighted Avg Shares Out (Dil) | 67.62M | 58.03M | 53.51M | 40.34M | 22.14M | 16.02M | 13.94M | 12.62M | 11.85M | 9.25M | 8.79M | 8.01M | 7.46M | 6.58M | 5.20M | 4.35M | 4.26M | 3.82M | 3.44M | 3.01M | 2.45M | 2.23M | 1.95M | 1.83M | 616.48K |
Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights
Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer On track to report overall survival results from randomized BRACELET-1 breast cancer study in H2 2024 Dosed first...
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET SAN DIEGO, Calif.
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report overall survival results from the randomized HR+/HER2- metastatic breast cancer BRACELET-1 trial in H2 2024 SAN DIEGO and CALGARY,...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer study continues to be expected in H2 2024 Pelareorep combination therapy advancing towards registration-enabling study in pancreatic cancer SAN DIEGO...
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Demonstrating pelareorep's synergy with modified FOLFIRINOX +/- atezolizumab in pancreatic cancer could expand the number of patients it may benefit Funding for the study comes from the US$5 million Therapeutic Accelerator Award from PanCAN SAN DIEGO, and CALGARY, AB ,...
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Oncolytics Biotech (ONCY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near...
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications SAN DIEGO and CALGARY, AB , May...
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
SAN DIEGO and CALGARY, AB , May 16, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Wednesday,...
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master protocol for pancreatic cancer with the intent to create a registration-enabling pathway...
Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript
Oncolytics Biotech, Inc. (NASDAQ:ONCY ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jon Patton - Director, Investor Relations and Communication Matthew Coffey - President, CEO & Director Thomas Heineman - Chief Medical Officer, Oncolytics...
Source: https://incomestatements.info
Category: Stock Reports